Speaker Profile
M.D.,Ph.D., Division Chief of Radiation and Cancer Biology, Stanford
Biography
Maximilian Diehn received his Bachelors Degree in Biochemical Sciencesfrom Harvard College and his M.D.Ph.D. in Biophysics from StanfordUniversity. He is a board certified Radiation Oncologist and specializes inthe treatment of lung cancers. Dr. Diehns current research program spanslaboratory, translational, and clinical studies. His areas of interestinclude cancer genomics, stem cell biology, and lung cancer biology. Hiswork has been recognized with a variety of awards, including the VFoundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris DukeClinical Scientist Development Award, and the NIH Directors New InnovatorAward. His group has developed an ultra sensitive and specific method fordetection of circulating tumor DNA called CAPP-Seq. Current work is focusedon applying CAPP-Seq to a range of clinical contexts, with an emphasis ontumor heterogeneity and minimal residual disease.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, UPMC
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions: Transforming Tumor Genomics into Therapy Guidance
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
• Christian Rolfo, Ohio State
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• Christopher Lieu, University of Colorado
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, Thermo Fisher
• Christian Rolfo, Ohio State
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
• Arul M. Chinnaiyan, University of Michigan
From Detection to Direction: Whole-Genome MRD for Therapy Guidance at Scale
• Phil Febbo, Veracyte
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
